This bill extends by 180 days the relevant periods of market exclusivity for drugs for rare diseases or conditions (i.e., orphan drugs) for which applications were submitted during the COVID-19 emergency period.
Actions
Feb 25, 2026
Referred to the House Committee on Energy and Commerce.